<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5B71FE8A-DC4E-41C4-81D2-E6D6A7AA0318"><gtr:id>5B71FE8A-DC4E-41C4-81D2-E6D6A7AA0318</gtr:id><gtr:name>Astex Pharmaceuticals</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:department>Sch of Biological Sciences</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5B71FE8A-DC4E-41C4-81D2-E6D6A7AA0318"><gtr:id>5B71FE8A-DC4E-41C4-81D2-E6D6A7AA0318</gtr:id><gtr:name>Astex Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DBAE7287-AB2B-4936-96E6-E62CA25F26C7"><gtr:id>DBAE7287-AB2B-4936-96E6-E62CA25F26C7</gtr:id><gtr:firstName>Daniel</gtr:firstName><gtr:surname>Longley</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0400302"><gtr:id>7A2C0A5E-CE25-451E-9BF5-6579DC724402</gtr:id><gtr:title>The role of c-FLIP in regulating chemotherapy-induced apoptosis.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400302</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2008-01-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>238500</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Astex Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Astex Therapeutics</gtr:department><gtr:description>Targeted use of SMAC mimetics in cancer</gtr:description><gtr:id>FD4704D1-BCFB-46B3-99E8-9C5DCB7A0C01</gtr:id><gtr:impact>Publications</gtr:impact><gtr:partnerContribution>Astex supplied their pre-clinical lead SMAC mimetic.</gtr:partnerContribution><gtr:piContribution>In vitro analysis of SMAC mimetics from Astex in lung malignancies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>CRUK volunteers</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>04085D2E-FE6D-4736-96B9-97E125127237</gtr:id><gtr:impact>A scientific description of cancer and our research designed to be accessible to lay people.

Hard to assess. Made me aware of the importance of our work as there were several cancer survivors in the audience.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Programme Grant</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>69FC394D-DE3B-4E39-91CF-157BC2A76C16</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Seeding Drug Discovery Initiative</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>86BF0F31-CB72-4EC4-B558-FAB9BF4C101D</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BLF Project Grant</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>British Lung Foundation (BLF)</gtr:fundingOrg><gtr:id>BD44F985-75E7-4213-BF37-2A8B64B0A16F</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinician Scientist Fellowship</gtr:description><gtr:end>2009-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>FBDE9D10-F43D-424A-B32E-CC85538625F1</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CFD8120F-C4E0-442F-B306-6373D0A5DD63"><gtr:id>CFD8120F-C4E0-442F-B306-6373D0A5DD63</gtr:id><gtr:title>Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6d586e2d2b3306f4f64054df7efc5a39"><gtr:id>6d586e2d2b3306f4f64054df7efc5a39</gtr:id><gtr:otherNames>Wilson TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FBA3FA0F-8894-4334-B1B4-27A8C4A6EBE3"><gtr:id>FBA3FA0F-8894-4334-B1B4-27A8C4A6EBE3</gtr:id><gtr:title>Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/29176821f32ee65380282032840af54e"><gtr:id>29176821f32ee65380282032840af54e</gtr:id><gtr:otherNames>Turkington RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CE9AB09F-D8E7-4A86-B1BD-0F25DB38455D"><gtr:id>CE9AB09F-D8E7-4A86-B1BD-0F25DB38455D</gtr:id><gtr:title>Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/07e26282084ca6e294a1fff6ee5c5be6"><gtr:id>07e26282084ca6e294a1fff6ee5c5be6</gtr:id><gtr:otherNames>Galligan L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BA4A3819-16A1-4D72-8A07-5A52E1256D6B"><gtr:id>BA4A3819-16A1-4D72-8A07-5A52E1256D6B</gtr:id><gtr:title>c-FLIP inhibits chemotherapy-induced colorectal cancer cell death.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/461e326558d5e1a53542f1280b5f78c7"><gtr:id>461e326558d5e1a53542f1280b5f78c7</gtr:id><gtr:otherNames>Longley DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9AE3C07B-345C-4792-A252-6F1F5C83CF8C"><gtr:id>9AE3C07B-345C-4792-A252-6F1F5C83CF8C</gtr:id><gtr:title>Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6c53400a0cd1759c0fbfa4fa8f5c08fb"><gtr:id>6c53400a0cd1759c0fbfa4fa8f5c08fb</gtr:id><gtr:otherNames>Stevenson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/13EB3438-6CA9-43B1-B03A-CBCE61007807"><gtr:id>13EB3438-6CA9-43B1-B03A-CBCE61007807</gtr:id><gtr:title>Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/480bff3e79edc19bff5fb798d69270f7"><gtr:id>480bff3e79edc19bff5fb798d69270f7</gtr:id><gtr:otherNames>McLornan D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7B70621F-6397-404F-8F27-C8547ED5E466"><gtr:id>7B70621F-6397-404F-8F27-C8547ED5E466</gtr:id><gtr:title>DED or alive: assembly and regulation of the death effector domain complexes.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6f9a18484b985e497089a2a0782c9c95"><gtr:id>6f9a18484b985e497089a2a0782c9c95</gtr:id><gtr:otherNames>Riley JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8E0991B1-2D48-40FC-9BC8-25BE2300762D"><gtr:id>8E0991B1-2D48-40FC-9BC8-25BE2300762D</gtr:id><gtr:title>A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0e3f1a99ba3563848bb1fcb4355c8fd6"><gtr:id>0e3f1a99ba3563848bb1fcb4355c8fd6</gtr:id><gtr:otherNames>Salvucci M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C74BBC16-0D3D-429F-A774-650219371C0E"><gtr:id>C74BBC16-0D3D-429F-A774-650219371C0E</gtr:id><gtr:title>Resistance mechanisms to cancer chemotherapy.</gtr:title><gtr:parentPublicationTitle>Frontiers in bioscience : a journal and virtual library</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c7469e65edb7e92ecbe54726637ca61b"><gtr:id>c7469e65edb7e92ecbe54726637ca61b</gtr:id><gtr:otherNames>Redmond KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1093-4715</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E49F9A11-3760-41DB-8E29-8BECDB82F428"><gtr:id>E49F9A11-3760-41DB-8E29-8BECDB82F428</gtr:id><gtr:title>HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8d161403181f192ffbb53a25901f28a8"><gtr:id>8d161403181f192ffbb53a25901f28a8</gtr:id><gtr:otherNames>Carson R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/55E5A818-43FE-4A12-B1C0-297F6EE293F1"><gtr:id>55E5A818-43FE-4A12-B1C0-297F6EE293F1</gtr:id><gtr:title>Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent.</gtr:title><gtr:parentPublicationTitle>European journal of cancer (Oxford, England : 1990)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9f57e2917f0fef98dee2ec243c855538"><gtr:id>9f57e2917f0fef98dee2ec243c855538</gtr:id><gtr:otherNames>Hurwitz JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0959-8049</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0C162002-C0F5-4722-AF0A-5FCFB601A8AF"><gtr:id>0C162002-C0F5-4722-AF0A-5FCFB601A8AF</gtr:id><gtr:title>Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b143d5b296a8694fc1993ee36800dfca"><gtr:id>b143d5b296a8694fc1993ee36800dfca</gtr:id><gtr:otherNames>Rogers KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/09636D0F-938E-42B6-BC04-6BB228C5E175"><gtr:id>09636D0F-938E-42B6-BC04-6BB228C5E175</gtr:id><gtr:title>A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0b02fc69b82b0e8546aaced1ca6bd390"><gtr:id>0b02fc69b82b0e8546aaced1ca6bd390</gtr:id><gtr:otherNames>Allen WL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DF611D98-EE9F-4C92-8237-D373FE2D210F"><gtr:id>DF611D98-EE9F-4C92-8237-D373FE2D210F</gtr:id><gtr:title>SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesothelioma.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d0af79ed6a0842919fc4d444f98bc01c"><gtr:id>d0af79ed6a0842919fc4d444f98bc01c</gtr:id><gtr:otherNames>Crawford N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E7A19DAB-FB02-4D1D-9C15-1353D56E109D"><gtr:id>E7A19DAB-FB02-4D1D-9C15-1353D56E109D</gtr:id><gtr:title>Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8a0342fbbf54732ab2747cdacb23e7a5"><gtr:id>8a0342fbbf54732ab2747cdacb23e7a5</gtr:id><gtr:otherNames>McLornan DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5D79E7D1-0663-4DB6-9B80-A9AA881EE0DC"><gtr:id>5D79E7D1-0663-4DB6-9B80-A9AA881EE0DC</gtr:id><gtr:title>Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/89ec6c78ba2795520a0999ff8712e4b2"><gtr:id>89ec6c78ba2795520a0999ff8712e4b2</gtr:id><gtr:otherNames>Kerr E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C0CDE057-74F8-40CD-B82E-B0FF2B18758C"><gtr:id>C0CDE057-74F8-40CD-B82E-B0FF2B18758C</gtr:id><gtr:title>In vitro and in vivo characterisation of a novel c-FLIP-targeted antisense phosphorothioate oligonucleotide.</gtr:title><gtr:parentPublicationTitle>Apoptosis : an international journal on programmed cell death</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/99cbdcf942f1a242bb736dae787a41ab"><gtr:id>99cbdcf942f1a242bb736dae787a41ab</gtr:id><gtr:otherNames>Logan AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1360-8185</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BE0D1C8A-C9AC-4DDC-A281-46C4A492F4B4"><gtr:id>BE0D1C8A-C9AC-4DDC-A281-46C4A492F4B4</gtr:id><gtr:title>Nanoencapsulation of ABT-737 and camptothecin enhances their clinical potential through synergistic antitumor effects and reduction of systemic toxicity.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fb5e167f9c4f242f6847ebad194f200e"><gtr:id>fb5e167f9c4f242f6847ebad194f200e</gtr:id><gtr:otherNames>Schmid D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/28CF6525-924D-419D-96F8-145D1659F88E"><gtr:id>28CF6525-924D-419D-96F8-145D1659F88E</gtr:id><gtr:title>c-FLIP: a key regulator of colorectal cancer cell death.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6d586e2d2b3306f4f64054df7efc5a39"><gtr:id>6d586e2d2b3306f4f64054df7efc5a39</gtr:id><gtr:otherNames>Wilson TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0EA5C952-7ABF-49F4-87B6-15E56F858BF0"><gtr:id>0EA5C952-7ABF-49F4-87B6-15E56F858BF0</gtr:id><gtr:title>Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ce394df71471879432e29a092611ba40"><gtr:id>ce394df71471879432e29a092611ba40</gtr:id><gtr:otherNames>McCourt C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/383252F5-CD3C-4488-9DEA-05446E988477"><gtr:id>383252F5-CD3C-4488-9DEA-05446E988477</gtr:id><gtr:title>Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6d586e2d2b3306f4f64054df7efc5a39"><gtr:id>6d586e2d2b3306f4f64054df7efc5a39</gtr:id><gtr:otherNames>Wilson TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6311D0E3-50FD-429E-9A61-AEAD6EE2BCF8"><gtr:id>6311D0E3-50FD-429E-9A61-AEAD6EE2BCF8</gtr:id><gtr:title>Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c690504953331fb806cb15021dc1c29b"><gtr:id>c690504953331fb806cb15021dc1c29b</gtr:id><gtr:otherNames>Wilson C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5214E32D-085F-442D-A58D-3D4221B44D06"><gtr:id>5214E32D-085F-442D-A58D-3D4221B44D06</gtr:id><gtr:title>Differential affinity of FLIP and procaspase 8 for FADD's DED binding surfaces regulates DISC assembly.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2ec5a88cfd14b070f41bfab5340b823c"><gtr:id>2ec5a88cfd14b070f41bfab5340b823c</gtr:id><gtr:otherNames>Majkut J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3B815660-CEB6-42C0-9150-08D3691A4A0D"><gtr:id>3B815660-CEB6-42C0-9150-08D3691A4A0D</gtr:id><gtr:title>Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/61f1137b32d1a3681f96a45410e4c1f6"><gtr:id>61f1137b32d1a3681f96a45410e4c1f6</gtr:id><gtr:otherNames>Van Schaeybroeck S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7C72B8B9-353E-4E37-BB92-7EFECE996A47"><gtr:id>7C72B8B9-353E-4E37-BB92-7EFECE996A47</gtr:id><gtr:title>Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6f9a18484b985e497089a2a0782c9c95"><gtr:id>6f9a18484b985e497089a2a0782c9c95</gtr:id><gtr:otherNames>Riley JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F5C453A0-654A-482D-ABC8-289A88B0E847"><gtr:id>F5C453A0-654A-482D-ABC8-289A88B0E847</gtr:id><gtr:title>FLIP: A Targetable Mediator of Resistance to Radiation in Non-Small Cell Lung Cancer.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6f2da794add3b23b04b1b955bde3dafa"><gtr:id>6f2da794add3b23b04b1b955bde3dafa</gtr:id><gtr:otherNames>McLaughlin KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400302</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>